免疫功能低下宿主严重急性呼吸综合征冠状病毒2聚合酶链反应长期阳性的抗病毒治疗结果：一项澳大利亚多中心回顾性病例系列研究
Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series.
作者信息
Bond K A, Dendle C, Guy S, Slavin M A, Smibert O, Ibrahim N, Kinsella P M, Morrissey C O, Moso M A, Sasadeusz J J
机构信息
Department of Microbiology, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
出版信息
Open Forum Infect Dis. 2024 Aug 7;11(8):ofae449. doi: 10.1093/ofid/ofae449. eCollection 2024 Aug.
Outcomes are presented for a multisite retrospective case series, describing a contemporary cohort of 22 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) polymerase chain reaction positivity who were retreated with antiviral therapy. For those with data available 14 and 30 days after commencement of antiviral therapy, 41% (9 of 22) and 68% (15 of 22), respectively, cleared COVID-19.
本文呈现了一个多中心回顾性病例系列的结果，描述了一组当代的22例免疫功能低下患者，这些患者持续性冠状病毒病2019（COVID-19）聚合酶链反应呈阳性，并接受了抗病毒治疗。对于那些在抗病毒治疗开始后14天和30天有可用数据的患者，分别有41%（22例中的9例）和68%（22例中的15例）清除了COVID-19。
Zotero 插件